Turnstone Biologics Corp. (TSBX)
(Delayed Data from NSDQ)
$0.36 USD
+0.01 (1.43%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $0.36 +0.01 (1.41%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Fundamental Charts
About Return on Equity (TTM)
Turnstone Biologics Corp.'s return on equity, or ROE, is -162.80% compared to the ROE of the Medical - Biomedical and Genetics industry of -61.64%. While this shows that TSBX has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
TSBX 0.36 +0.01(1.43%)
Will TSBX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TSBX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TSBX
Turnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock?
TSBX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TSBX
Turnstone Biologics to be acquired by XOMA Royalty
Turnstone Biologics (TSBX) Agrees to Acquisition by XOMA Royalty | TSBX Stock News
Xoma to acquire Turnstone Biologics for $0.34 in cash per share
Xoma to acquire Turnstone Biologics for $0.34 in cash per share
Turnstone Biologics Corp. Enters Merger Agreement with XOMA